Expression of the breast cancer susceptibility gene, BRCA1, is induced by 17-b estradiol (E 2 ) in estrogen receptor containing breast cancer cell lines. Our previous studies have shown that BRCA1 transcription is also regulated with the cell cycle, reaching maximal levels just before the onset of DNA synthesis. In this study, we have examined whether the estrogen induction of BRCA1 is direct or is a result of the mitogenic activity of the hormone. Four lines of evidence lead us to conclude that E 2 induces BRCA1 primarily through an increase in DNA synthesis: (1) The kinetics and magnitude of induction are dierent from the directly E 2 inducible gene, pS2; (2) Induction of BRCA1, but not pS2, is blocked by cycloheximide indicating that de novo protein synthesis is required; (3) Other hormonal and growth factor treatments that induce DNA synthesis have a similar eect, including IGF-1, EGF and DNA synthetic ares induced by tamoxifen and retinoic acid; (4) BRCA1 genomic fragments near the 5' end of the gene containing putative estrogen response elements fail to respond to E 2 when transfected into breast cancer cell lines. The most consistent explanation for these ®ndings and other published studies is that BRCA1 transcription is induced as a result of the mitogenic activity of E 2 in estrogen receptor positive cells.
Introduction
More than half of hereditary breast/ovarian cancer families can be attributed to mutations in the breast cancer susceptibility gene, BRCA1 Easton et al., 1995; Ford et al., 1995) . However, very few mutations have been found in sporadic ovarian cancer and, to date, there have been no somatic mutations described in breast cancers Merajver et al., 1995; Matsushima et al., 1995) . Two clues as to its possible function lie in regions of homology to the family of zinc ®nger transcription factor proteins and to the secreted granin proteins , but the speci®c role of the gene remains unknown.
While there are very few somatic mutations in cancer, several lines of evidence suggest that BRCA1 may play a signi®cant role in the etiology of sporadic breast cancer. Thompson et al. (1995) found that BRCA1 expression was signi®cantly decreased in invasive breast cancers when compared to normal mammary tissue and preinvasive cancers. Overexpression of BRCA1 in several breast and ovarian cancer cell lines resulted in growth inhibition in vitro and for the MCF-7 breast cancer line, in vivo as well (Holt et al., 1996) . Conversely, inhibition of BRCA1 expression by antisense oligonucleotides resulted in an increased rate of growth of a breast cancer cell line. These results suggested that decreased BRCA1 expression may be a common event in sporadic breast cancer that leads to loss of growth control. Another potential mechanism was described by Chen et al. (1995) who found that the BRCA1 protein was predominantly located in the nucleus in normal cells and cancers of other tissues, but that breast cancers contained BRCA1 in the cytoplasm. Therefore, they suggested that aberrant subcellular localization of the BRCA1 protein may inactivate this tumor suppressor gene in many non-familial breast cancers. However, there are still serious questions regarding the location and size of the BRCA1 protein Scully et al., 1996) .
Studying the expression of this gene may be important both in understanding its role, if any, in sporadic cancers and in discovering its normal cellular function. Two groups have described the developmental patterns of expression of murine BRCA1 (Marquis et al., 1995; Lane et al., 1995) . Expression at the RNA level is high in rapidly proliferating tissues, particularly those that are undergoing dierentiation. Expression is also induced in the mammary gland during puberty, pregnancy, and lactation and in response to exogenously added estrogen plus progesterone in ovariectomized animals. Consistent with this ®nding, Gudas et al. (1995) reported that BRCA1 expression was induced by estrogen and progesterone in breast cancer cell lines containing these nuclear hormone receptors. We and others have shown that BRCA1 expression is regulated with the cell cycle in both normal mammary epithelial cells and breast and ovarian cancer cell lines (Vaughn et al., 1996; Chen et al., 1996) . Expression of BRCA1 mRNA is induced maximally just before cells enter the S phase of the cell cycle. These ®ndings suggested that it would be dicult to distinguish between a direct hormone response and a secondary response coupled to hormone induced mitogenesis. In the current study, we have further investigated this phenomenon and conclude that BRCA1 expression is linked to a promotion of DNA synthesis induced by these hormones and is unlikely to be a direct estrogen responsive gene.
Results
The breast cell lines MCF-7, ZR-75-1 and T47-D contain detectable levels of the estrogen receptor (ER) protein while the SK-BR-3 cell line is ER negative. Each of these cell lines was cultured for 24 h in medium lacking serum and phenol red and then treated with 10 78 M 17-b estradiol (E 2 ) for 5 to 24 h (Figure 1 ). We observed variable levels of induction of BRCA1 mRNA in the three ER(+) cell lines over the course of a 24 h treatment whereas there was no elevation in BRCA1 mRNA in the ER(7) SK-BR-3 cell line. While the level and time course of induction was highly variable in the three ER(+) cell lines, levels of mRNA for the classic estrogen responsive gene, pS2, paralleled the induction of BRCA1. Increased expression for both of these genes could be detected as early as 5 h after the addition of E 2 in MCF-7 and ZR-75-1 cells with maximal induction at 24 h. Only a slight increase in BRCA1 and pS2 was observed in T47-D cells after 24 h of treatment consistent with the relatively low ER content of these cells (58 fmol/mg of protein).
We used three mechanistically dierent antagonists to modulate the estrogenic induction of BRCA1 in MCF-7 cells: ICI182,780, keoxifene and tamoxifen citrate (McDonnell et al., 1995a) . Cells were cultured for 24 h in medium containing charcoal-stripped serum and then treated with hormone and antagonist for an additional 24 h. At a 100-fold molar excess, both ICI and keoxifene completely inhibited the induction of BRCA1 by E 2 (Figure 2a ). Tamoxifen treatment in the absence of E 2 induced BRCA1 mRNA levels contrary to expectation. Both the ICI compound and keoxifene also inhibited estrogen induced expression of pS2.
Regulation of these genes diverged in that tamoxifen induced BRCA1 but not pS2 expression. The results were not inconsistent with a direct eect of estrogen on the BRCA1 gene except for the action of tamoxifen which is more fully described below.
Our previous results showed that expression of BRCA1 is regulated with the cell cycle, both in normal mammary epithelial cells and cancer cell lines (Vaughn et al., 1996) . Expression is elevated just prior to entry into S phase, therefore, we considered that induction of BRCA1 by E 2 might be secondary to its mitogenic eect on these cell lines. Several approaches were used to investigate this issue, primarily in MCF-7 cells. We initially determined whether there was a direct correlation between elevated expression of BRCA1 and the number of cells in S phase. The percentage of cells undergoing DNA synthesis was measured by¯ow cytometry of BrdU labeled and propidium iodide stained cells ( Figure 2b ). Addition of 10 78 M E 2 to estrogen depleted medium resulted in a fourfold increase in the number of MCF-7 cells in S phase by 24 h of treatment. The two eective antiestrogens, ICI and keoxifene, prevented this induction consistent with their eects on BRCA1 expression. Tamoxifen, however, did not repress the mitogenic activity of 17-b estradiol at these concentrations. This is also consistent with the failure of tamoxifen to prevent BRCA1 induction. From these experiments, we were unable to separate BRCA1 induction from E 2 induced mitogenesis.
Other mitogenic stimuli should also elicit a similar response if BRCA1 expression is speci®cally linked to growth. To test this, we treated MCF-7 cells in the absence of estrogens with the known mitogens, epidermal growth factor (EGF) and insulin-like growth factor I (IGF-I) (Imai et al., 1982; Freed and Herington, 1989) (Figure 3 ). Cells treated over the course of 36 h with both peptide hormones showed an increase in BRCA1 mRNA levels. IGF-I, which induced higher levels of DNA synthesis than EGF (data not shown) also induced higher levels of BRCA1 providing further evidence that expression is primarily linked to growth. Protein extracts from these cells were also prepared and the BRCA1 protein was detected using both polyclonal (C-20) and monoclonal antibodies (MS110). Both antisera detected a protein of approximately 220 kd whose abundance tracked with the levels of BRCA1 mRNA. While the confusion over the BRCA1 protein is not entirely resolved, the emerging consensus is that these two antisera both recognize a 220 kd protein which is authentic BRCA1 (Chen et al., 1996; Wilson et al., 1996; Scully et al., 1996) . In addition, the polyclonal antiserum detects the 170 kd epidermal growth factor receptor (detected on our blots but not shown).
Tamoxifen not only failed to inhibit E 2 induced BRCA1 expression and mitogenesis, it consistently induced BRCA1 expression by itself. Since tamoxifen can act as an estrogen agonist in the context of certain promoters (McDonnell et al., 1995b; Ramkumar and Adler, 1995) , we further investigated this phenomenon. For these experiments, MCF-7 cells were cultured in serum free medium for 1 day prior to treatment. Cells were then treated with varying concentrations of E 2 (10 78 to 10 710 M) either with or without 10 77 M 4-hydroxytamoxifen (4HT, the active metabolite of tamoxifen has at least 10-fold greater activity (Tzukerman et al., 1994) ). The levels of BRCA1 and pS2 mRNA and the percentage of cells undergoing DNA synthesis were measured. In serum free medium alone, approximately 7% of the cells were in S phase ( Figure  4a ). The addition of 4HT doubled the number of cells undergoing DNA synthesis (tamoxifen¯are). E 2 alone resulted in a ®vefold increase in the percentage of cells in S-phase over the range of concentrations used. 4HT inhibited estrogen induced mitogenesis but only when it was in 100-and 1000-fold molar excess over E 2 . At a 1000-fold excess (10 77 M 4HT: 10 710 M E 2 ), the number of cells in S phase was reduced to the level of 4HT alone, i.e. twofold over control cells lacking any hormone. BRCA1 expression paralleled the S phase values in each case (Figure 4b ). All treated cells contained BRCA1 mRNA levels that were elevated over the control. A decrease in the estrogen induction was apparent only when 4HT was at a 1000-fold molar excess, reducing expression (and % S phase) to the same level as 4HT alone (approximately twofold less than maximal E 2 induced expression and S phase). pS2 expression was much more sensitive to 4HT inhibition. E 2 yielded more dramatic induction and 4HT blocked the induction at a lower ratio. This experiment is not de®nitive proof that BRCA1 is not directly responsive to estrogen since dierent estrogen responsive promoters may have dierent pro®les with respect to estrogen induction and tamoxifen sensitivity.
In an attempt to determine whether BRCA1 expression could be inhibited by growth inhibitors, we treated MCF-7 cells with all-trans retinoic acid (RA). Over the course of a 7 ± 10 day treatment with 10 76 M RA, growth of these cells is inhibited by greater than 75% compared to control cultures (JRM, unpublished data). However, instead of a decrease in BRCA1 expression, we observed that RA treatment increased the level of BRCA1 mRNA during a 24 h treatment. To further analyse this response, we measured the eects of RA on DNA synthesis and BRCA1 expression in serum starved cells. As with tamoxifen, RA induced a transient increase in DNA synthesis at 24 h (Figure 5a ), however neither compound induced DNA synthesis to the same extent as E 2 (37% compared to 27% and 15% for RA and Figure 3 Eect of mitogenic peptide hormones on BRCA1 expression in MCF-7 cells. Cells were cultured in serum and phenol red free medium for 48 h prior to treatment with 50 ng/ml of IGF-I or 25 ng/ml of EGF. Total RNA and protein were extracted from separate aliquots of identically treated cells.
Northern blotting was performed as described in Figure 1 . BRCA1 protein was detected using the C-20 polyclonal antiserum which also recognizes the epidermal growth factor receptor (not shown on this portion of the blot). The same blot was stripped and reprobed with a BRCA1 mouse monoclonal antibody (MS110) which detected a protein of identical mobility and kinetics of induction tamoxifen respectively). This is consistent with the lower level of BRCA1 induced by these compounds compared to E2. By 48 h, both RA and tamoxifen treated cells returned to baseline values for DNA synthesis. The transient induction of DNA synthesis with both agents again correlated with the levels of BRCA1 mRNA (Figure 5b ). This eect with RA was not observed with other breast cell lines or primary mammary epithelial cells (SK-BR-3, ZR-75-1, MDA-MB-468, and normal mammary epithelial cells, data not shown). That is, no other cell line responded to RA by inducing BRCA1 or DNA synthesis. These experiments provide another link between BRCA1 expression and the induction of DNA synthesis. Ongoing protein synthesis is not required for the direct induction of estrogen responsive genes such as pS2 (Brown et al., 1984) . Therefore, we next tested whether E 2 induced BRCA1 expression was sensitive to the inhibition of protein synthesis. MCF-7 cells were grown in charcoal-stripped medium and then pretreated with 50 mM cycloheximide for 1 h before the addition of E 2 . After 12 h of E 2 treatment in the presence of cycloheximide, pS2 expression was still induced compared to the control, however BRCA1 mRNA levels were comparable to those found in untreated cells (Figure 6 ). Therefore, ongoing protein synthesis is required for estrogenic induction of BRCA1 transcription, consistent with an indirect mechanism of action.
We had previously identi®ed putative estrogen response elements (ERE) within a BRCA1 genomic clone (P1-1141) using a functional screen in yeast, however the precise location of these elements within the 100 kb BRCA1 sequence was not mapped (Norris et al., 1995) . These elements are embedded within a speci®c class of Alu repeat making them dicult to precisely map. However, a similar repeat containing a consensus Alu-ERE is located within intron 1 of the BRCA1 gene . Another putative ERE (containing a consensus half-site) is located upstream of the start of transcription. Fragments containing these two sequences were ampli®ed from P1-1141 and cloned into a luciferase expression vector. The BRCA-ER1 sequence contains the Alu element and is located within intron 1 of the BRCA1 gene while BRCA-ER2 is located upstream of exon 1A terminating 253 bp upstream of the start of transcription. In response to E 2 , these clones induced luciferase 5 ± 10-fold in HepG2 cells (an ER(7) human hepatocellular carcinoma cell line) when co-transfected with the estrogen receptor Figure 1 (data not shown). We then tested these elements in both MCF-7 cells and the ER(7) SK-BR-3 cell line (Figure 7a and b) . The consensus ERE vitellogenin promoter was used as a positive control. In both cell lines, the vitellogenin promoter was stimulated by E 2 with induction in the SK-BR-3 cells dependent upon co-transfected estrogen receptor. However, unlike the HepG2 cell line, the BRCA1 elements were completely non-responsive to E 2 in both breast lines, with or without co-transfected estrogen receptor. While these sequences in the 5' region of the BRCA1 gene may have the capacity to function as estrogen response elements, they fail to respond to E 2 in the context of breast cancer cell lines. We were, therefore, unable to locate a functional ERE in the BRCA1 gene (using both a genetic selection system in yeast and homology searches in the 5' promoter region), however the existence of such an element cannot be entirely excluded.
Discussion
The purpose of this study was to determine whether transcription of the breast cancer susceptibility gene, BRCA1, is directly responsive to estrogen. If BRCA1 turned out to be an estrogen responsive gene, it could begin to explain why germ-line mutations lead to a restricted pattern of cancers, primarily of the breast and ovarian epithelium, two cell types that normally contain comparable levels of the receptor for this steroid hormone (Zeimet et al., 1994) . Evidence for estrogen regulation of BRCA1 has come from analysis of tissue and developmentally regulated expression in the mouse (Marquis et al., 1995; Lane et al., 1995) . In addition, treatment of ovariectomized mice with exogenous estrogen plus progesterone resulted in increased BRCA1 mRNA expression in the breast epithelium (Marquis et al., 1995) . Breast cancer cell lines have also been shown to induce BRCA1 expression in response to estrogen and progesterone when the lines express high levels of the cognate receptors for these hormones (Gudas et al., 1995) . The interpretation of these studies is complicated by our ®nding that the BRCA1 mRNA is regulated with the
28S
Figure 6 Cycloheximide treatment blocks E 2 induced BRCA1 expression but not pS2 expression. MCF-7 cells were cultured in medium containing 10% charcoal-stripped FBS for 24 h and then pretreated for 1 h with 50 mM cycloheximide (for those cultures labeled`CH'). Cultures were then treated for 12 h with the indicated compounds; CH, 50 mM cycloheximide; E 2 , 10 78 M 17-b estradiol. RNA was harvested and BRCA1 and pS2 detected as described in Figure 1 a b Figure 7 Lack of estrogen responsiveness of BRCA1 genomic sequences containing putative estrogen response elements (ERE). Triplicate cultures were transfected with potential EREs linked to the luciferase gene and a CMV-b-gal plasmid. Luciferase activity was normalized to b-galactosidase activity in each set of transfections. (a) MCF-7 cells were transfected with the vitellogenin consensus ERE as a positive control. Two genomic fragments from the BRCA1 P1 (P1141) were ampli®ed and cloned into pBL-TK-Luc. BRCA1-ER1 is an 840 bp fragment located in intron 1 and BRCA1-ER2 is a 1200 bp fragment located upstream of exon 1A. No stimulation of luciferase activity was observed at either concentration of E 2 used. (b) The same experiment was performed with the ER(7) SK-BR-3 cell line. In this experiment, cells were also co-transfected with the estrogen receptor vector, pRST7-hER. Only upon co-transfection with the estrogen receptor was expression stimulated from the vitellogenin promoter. Again, no stimulation was observed using the two BRCA1 genomic clones cell cycle with maximal levels attained just before the onset of DNA synthesis (Vaughn et al., 1996; . Therefore, the question which needed to be addressed was whether estrogen was directly influencing expression of BRCA1 or if this was an indirect response to the hormone's mitogenic eect. The ®ndings presented in this paper indicate that estrogen does not directly induce expression of BRCA1 even though there are consensus estrogen response elements located near the 5' end of the gene.
Evidence supporting this conclusion can be summarized as follows: (1) E 2 induction of BRCA1 is much lower and not as sensitive to the antagonistic eect of tamoxifen when compared to the pS2 gene which is directly induced by hormone occupied estrogen receptor (Berry et al., 1988) . Gudas et al. described the estrogen response of BRCA1 as being delayed compared to pS2 and concomittant with cyclin A expression suggesting that it was linked to proliferation (Gudas et al., 1995) . We have also observed this delay in some experiments. We attribute the variability in the magnitude and kinetics of this response to the density of the cells on the dish which can markedly in¯uence the mitogenic response; (2) The response is blocked by cycloheximide, whereas pS2 expression is not indicating that pre-existing hormone receptor is not sucient for E 2 mediated induction; (3) In no instance have we been able to decouple increased expression of BRCA1 from an increase in the percentage of cells undergoing DNA synthesis. Experiments were done using combinations of estrogen, potent estrogen antagonists, tamoxifen, EGF, IGF-I and retinoic acid. In each case, eects on DNA synthesis were paralleled by eects of a similar magnitude on BRCA1 mRNA levels. Surprisingly, we found that in quiescent serum starved MCF-7 cells, 10 78 M E 2 by itself was sucient to induce a large percentage of the cells to enter DNA synthesis. These conditions also induced BRCA1 expression; (4) A screen for estrogen responsive elements in the BRCA1 gene yielded two candidate sequences that map near the 5' end of the gene. However, these fragments were both completely non-responsive to E 2 in MCF-7 and SK-BR-3 cells when supplied with added estrogen receptor. Both of these elements were highly responsive in the human hepatoma cell line, HepG2 (Norris et al., 1995) highlighting the highly context dependent nature of these response elements. This suggests that BRCA1 may be directly estrogen responsive in other cell types or that other cells are more promiscuous activators of these elements (Katzenellenbogen et al., 1996) . These results coupled with previous published data on the cell cycle regulation of this gene lead us to conclude that E 2 (and other mitogenic hormones) aects BRCA1 transcription indirectly.
Studies of mouse BRCA1 also tend to support this conclusion. While expression in the mammary gland appears tied to certain hormonal cues such as puberty and pregnancy, these stages are also characterized by rapid proliferation (Marquis et al., 1995) . In ovariectomized animals, treatment with estrogen alone had little or no eect on BRCA1 expression in the breast. Only when a combination of estrogen and progesterone was administered did expression increase in the developing alveolar epithelial cells. This is consistent with the combined action of these hormones being required for the growth of the mammary gland (Haslam, 1987; Wang et al., 1990) . While a direct regulatory link between estrogen and BRCA1 would have been an attractive mechanism to explain why germ-line mutations in the BRCA1 gene predispose to breast and ovarian cancer, it appears that other explanations must be sought.
Materials and methods

Cell culture
Breast cancer cell lines were obtained from the American Type Culture Collection (ATCC) and maintained in RPMI1640 containing 10% fetal bovine serum (FBS). Normal mammary epithelial cells were grown in DFCI-1 (Band et al., 1990) . For hormone treatments, cell lines were either cultured in phenol red-free RPMI containing 10% charcoal-stripped FBS or phenol red-free RPMI1640 with no serum for 24 h prior to treatment.
Hormone and growth factor treatments
Cells were treated with 17-b estradiol (Sigma), tamoxifen citrate (Sigma), 4-hydroxytamoxifen (a gift from P®zer, Inc.), ICI182,780 (gift from Alan Wakeling, Zenaca Pharmaceuticals), keoxifene (gift from Eli Lilly, Inc.), insulin-like growth factor I (Sigma) and epidermal growth factor (Sigma). Controls for each treatment consisted of identical cultures treated with the vehicle alone.
RNA extraction and Northern blotting
After the indicated treatments and times, cells were harvested by trypsinization, washed once with phosphate buered saline and stored as a pellet at 71008C until extracted. Extractions were performed using the Trizol reagent (Gibco/BRL). Northern blotting and hybridizations were performed as previously described (Marks et al., 1989) . A 2519 bp fragment including most of exon 11 of the human BRCA1 gene (nucleotides 1026 to 3545, Genbank U14680) and a pS2 cDNA (obtained from the ATCC) were used as probes.
Immunoblotting
Total protein extracts were prepared as previously described (Elbendary et al., 1994) with the addition of the following protease inhibitors: 1 mM PMSF, 25 mg/ml leupeptin, 25 mg/ml aprotinin, 1 mM benzamidine and 10 mg/ml soybean trypsin inhibitor (all from Sigma). Extracts were quantitated by the Bradford method (BioRad) and 100 mg of each was run on a 5% SDS ± PAGE, blotted to a solid support and probed with 1.0 mg/ ml of the C-20 BRCA1 antibody (Santa Cruz). Binding was visualized by reacting with a horseradish peroxidase conjugated goat anti-rabbit antibody (Amersham) followed by detection with ECL reagents (Amersham). The speci®city of the C-20 antibody was con®rmed by stripping and reprobing the same and other blots with the BRCA1 monoclonal antibody from Oncogene Science (MS110).
Cell cycle analysis
Parallel cultures of cells were pulse labeled with BrdU for 1 h prior to harvesting. Detection of incorporated BrdU and staining with propidium iodide was performed as previously described (Vaughn et al., 1995) . Two channel ow cytometric analysis on a minimum of 10,000 events was performed on a Becton Dickinson FACStar Plus. The percentage of cells in S phase was quantitated using the quadplot function.
Luciferase assay
Two clones were derived using the published 5' untranslated region of the BRCA1 gene by PCR . The BRCA-ER1 sequence containing an Alu element is 840 bp and is located within intron 1A of the BRCA1 gene (from nucleotide 1893 ± 2732 Genbank accession no. U37574) while BRCA-ER2 is 1200 bp and is located upstream of exon 1A (nucleotide 150 ± 1350). These clones both contain putative estrogen response elements based upon consensus sequence analysis and comparison to other estrogen responsive elements. These sequences were cloned into pBL-TK-Luc for functional analysis. Plasmids were delivered to cells via Lipofectin (Gibco/BRL) in Optimem medium (Gibco/BRL) as described (Vaughn et al., 1995) . In some experiments, cells were also co-transfected with the estrogen receptor expression vector, pRST7-hER (Dana et al., 1994) . Brie¯y, each transfection was done in triplicate using 3 mg of DNA in total including 0.5 mg of pCMV-bgal to normalize for transfection eciency. Lipofectin remained on the cells for 4 h after which the medium was changed to phenol red-free RPMI containing 10% charcoal-stripped FBS. Transfected cells were cultured for a total of 20 h before treatment with hormones or antihormones for an additional 24 h. Subsequently, the cells were lysed and assayed for luciferase and bgalactosidase activity.
